Insider buying last 90 days
No open-market insider purchases were filed for CGON in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CGON insider filing, plotted on the chart in Gekko.Open CGON in Gekko
NASDAQ: CGON
CG Oncology (CGON) Stock Analysis & Forecast
Sep 28 close
$69.61+2.46 (+3.7%)
Gekko Brief
AI summaryThis week's news centers on short interest and an insider transaction rather than company operations. CG Oncology's short interest stood at 11.25 million shares as of September 15, representing 13.34% of its public float, a 1.24% decrease from the previous report, with a short interest ratio of 17.0 days to cover. Separately, officer Ambaw Bellete filed a Rule 144 notice for an intended sale of 30,787 shares tied to a stock option exercise, following a prior $7.9 million sale.
CGON closed at $69.61, up 3.7%, sitting between its 50-day average of $74.09 and 200-day average of $63.34. Momentum shows a one-month return of -11.9% against a six-month return of 7.7% and a one-year return of 90.8%, with the 52-week range spanning $35.80 to $80.97. The GekkoIndex reads 65.1, placing the stock in the Accumulation zone, up 12.5 over five days. Price sits 13.9% below Gekko Fair Value of $80.89.
Earnings are scheduled for 13 November 2026, 45 days out and beyond a typical 20-trading-day window; the prior report on 8 May showed an EPS miss of -0.71 against a -0.58 estimate, with a 0.2% reaction, and 3 beats across the last 8 quarters. Options activity shows 1 unusual signal over the past 30 days, entirely put premium at $252,395 with no call premium. Two trailblazer holders are noted. Ten covering analysts carry a consensus buy rating with a $91.08 target, implying 30.8% consensus upside.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
CG Oncology price vs fair value
Close $69.61200-day averageGekko Fair Value $80.89
CG Oncology quick facts
- Market cap
- $6.14B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.69
- Revenue, TTM
- $6.23M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.24
- Volume
- 1.72M avg 916,236
- 1-year return
- +90.8%
- Typical daily move
- ±5%
- Typical 20-day move
- ±8.5%
- 50-day average
- $74.09
- 200-day average
- $63.34
- Next earnings
- Nov 13
- Shares outstanding
- 88.64M
CG Oncology swing-trade checklist
CG Oncology scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $69.61 sits between the 50-day ($74.09) and 200-day ($63.34) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.1, Accumulation
Reading 65.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
13.9% below
Price is 13.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 45 days
Next report Nov 13, 2026, 45 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
CG Oncology stock chart and price history
CG Oncology closed at $69.61 on Sep 28, 2026, +90.8% over the past year, inside a 52-week range of $35.80 to $80.97.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −11.9%
- 3 months
- −5.6%
- 6 months
- +7.7%
- 1 year
- +90.8%
The full CGON chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CGON in Gekko
Follow CG Oncology through every session
Put CGON on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CGON in GekkoFree for 7 days. No credit card required.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on treating bladder cancer in the United States. Its work centers on a single investigational therapy, cretostimogene grenadenorepvec, an oncolytic immunotherapy being studied across multiple stages of bladder cancer, including cases where prior BCG treatment has failed and cases considered high risk or intermediate risk.
The company runs a series of clinical programs testing cretostimogene both as a standalone treatment and in different patient groups, including those with BCG-unresponsive disease, papillary tumors, and patients following surgical removal of tumors through TURBT. These programs span phase 2 and phase 3 trials, each designed to examine safety and effectiveness of the therapy in a specific bladder cancer population. As a clinical-stage company, its business is built around advancing this pipeline of trials rather than selling an approved product.
CG Oncology was founded in 2010 under the name Cold Genesys, Inc. and adopted its current name in June 2020. It is headquartered in Irvine, California, and its shares are listed on the NASDAQ under the ticker CGON.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- cgoncology.com
CG Oncology GekkoIndex: the smart money zone
CG Oncology’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.1, in the Accumulation zone, up 12.5 points over five sessions.
65.1Accumulation
Up 12.5 points over five sessions, from the Neutral zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | +4.3% | +16.7% | ||
| Accumulation (current zone) | 174 | +2.3% | +5.3% | ||
| Neutral | 420 | +0.1% | +0.8% | ||
| Distribution | 35 | −0.2% | +4.1% | ||
| Selling | 2 | Too few readings yet | |||
Average CGON share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the CGON price, zone by zone.Track CGON in Gekko
Is CG Oncology stock overvalued? Gekko Fair Value
CG Oncology trades 13.9% below Gekko Fair Value of $80.89, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what CG Oncology shares are worth, recalculated every trading day.
$80.89
Gekko Fair Value, Sep 29, 2026
13.9% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CGON in Gekko
CG Oncology insider and Congress trading
No open-market insider purchases were filed for CG Oncology, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CGON were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CGON, plotted on the chart in Gekko.Open CGON in Gekko
Unusual options activity last 30 days
1signal, 0% of the flagged premium in calls.
Latest: Bearish flow on Sep 10, $252K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold CGON.
1added1opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
CG Oncology earnings: next date and track record
CG Oncology reports on Nov 13, 2026 (45 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 13, 2026
45 days away
- EPS estimate
- −$0.86
- Revenue estimate
- $548K
3 of 8reports beat the EPS estimate
±5.2%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 8, 2026 | −$0.71 est −$0.58 | $1.08M est $453K | +0.2% |
| Feb 27, 2026 | −$0.51 est −$0.61 | $2.30M est $451K | +2.9% |
| Nov 14, 2025 | −$0.57 est −$0.56 | $1.67M est $59K | +9.2% |
| Aug 8, 2025 | −$0.54 est −$0.49 | — est $82K | −1.6% |
| May 13, 2025 | −$0.45 est −$0.39 | $52K est $118K | −3.9% |
| Mar 28, 2025 | −$0.48 est −$0.41 | $456K est $124K | −9.1% |
| Nov 14, 2024 | −$0.30 est −$0.42 | — | −6.4% |
| Aug 8, 2024 | −$0.28 est −$0.42 | $111K | +8.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
CG Oncology stock forecast and analyst price targets
Analysts’ average 12-month price target for CG Oncology is $91.08, +30.8% from the last close, from 10 firms rating the stock in the last 90 days.
$91.08consensus 12-month target, +30.8% from the last close
Now $69.61Avg $91.08
Low $79High $108
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 10 | Truist Financial | — | — |
| Aug 20 | UBS | $90 | +29.3% |
| Aug 17 | Morgan Stanley | $93 | +33.6% |
| Aug 11 | Truist Financial | $85 | +22.1% |
| Aug 7 | Truist Financial | $85 | +22.1% |
+5.3%average 20-day move after past Accumulation readings
±5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
CG Oncology market cap and key statistics
CG Oncology’s market cap is $6.14B and revenue of $6.23M over the last twelve months.
Valuation
- Market cap
- $6.14B
- EPS, TTM
- −$2.69
- Gekko Fair Value
- $80.89
Trading
- Volume
- 1.72M
- Avg volume, 20 days
- 916,236
- 52-week high
- $80.97
- 52-week low
- $35.80
- Shares outstanding
- 88.64M
Financials
- Revenue, TTM
- $6.23M
- Profit margin
- 0%
- Return on equity
- -26.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.24
- Typical daily move
- ±5%
- Typical 20-day move
- ±8.5%
CG Oncology stock news this week
2 headlines about CG Oncology from the past week, newest first, each linking to the publisher.
- CG Oncology (CGON) Short Interest & Short Float | Updated Sep 2026MarketBeat, Sep 24
- After $7.9M sale, CG Oncology (NASDAQ: CGON) officer plans more stock tradesStock Titan, Sep 22
CG Oncology peers
CG Oncology’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
CG Oncology stock FAQ
What is CG Oncology’s market cap?
CG Oncology’s market cap is $6.14B at the Sep 28, 2026 close of $69.61, with 88.64M shares outstanding.
What is the CG Oncology stock forecast?
The consensus analyst 12-month price target for CG Oncology is $91.08, +30.8% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is CG Oncology stock overvalued or undervalued?
On Gekko’s estimate CG Oncology is undervalued: the Sep 28, 2026 close of $69.61 is 13.9% below Gekko Fair Value of $80.89. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does CG Oncology report earnings next?
CG Oncology is expected to report on Nov 13, 2026 (45 days away). Analysts expect earnings of −$0.86 per share on revenue of $548K. CG Oncology beat the earnings estimate in 3 of its last 8 reports, moving 5.2% on average across the report.
What is CG Oncology’s 52-week high and low?
CG Oncology’s 52-week high is $80.97 and its 52-week low is $35.80; it closed at $69.61 on Sep 28, 2026, +90.8% over the past year.
Is CG Oncology stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in CG Oncology?
Gekko flagged 1 unusual options signal in CG Oncology over the last 30 days, with $0 of flagged premium in calls and $252K in puts. The latest, bearish flow, was on Sep 10, 2026 with $252K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See CG Oncology the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.